OraSure Technologies, Inc. — 2013 Form 10-K
Business context and reporting period. This annual report covers the fiscal year ended December 31, 2013; quarterly figures below identify the fourth quarter where relevant. OraSure develops and sells diagnostic tests and oral-fluid collection products, including HIV and HCV tests, and cryosurgical products. Its two reportable segments are OSUR and DNA Genotek (DNAG), which sells molecular sample-collection systems.
Financial performance and position
| Metric | 2013 | 2012 |
|---|---|---|
| Net revenue | $98.9 million | $87.8 million |
| Gross profit / gross margin | $58.6 million / 59% | $55.6 million / 63% |
| Operating loss | $12.2 million | $16.3 million |
| Net loss / loss per share | $11.2 million / $0.20 | $15.1 million / $0.29 |
| Cash from (used in) operations | $8.4 million | ($5.4 million) |
| Cash and cash equivalents at year-end | $93.2 million | $87.9 million |
| Working capital at year-end | $100.6 million | $103.5 million |
| Long-term debt | None | None |
Revenue grew 13%; product revenue rose 15%. International revenue was $21.7 million, or 22% of total revenue. Year-end total assets were $184.2 million and stockholders’ equity was $161.1 million. Operating cash flow included the $8.3 million Roche settlement payment. Capital expenditures were $2.5 million; management expected approximately $4.0 million in 2014. The company said existing cash should fund operating and capital needs for at least the next 12 months.
Material changes and operating drivers
- Infectious-disease testing revenue increased 19% to $51.0 million. OraQuick revenue rose 20% to $49.9 million, led by the In-Home HIV test and international HCV sales; domestic professional HIV sales declined 6%.
- DNAG revenue increased 43% to $20.4 million, primarily from increased commercial-customer orders. DNAG generated $0.7 million of operating income versus a $2.9 million operating loss in 2012.
- OSUR revenue increased 7% to $78.6 million, but OSUR reported a $12.8 million operating loss. Substance-abuse testing revenue fell 9%, cryosurgical revenue fell 3%, and insurance risk-assessment revenue fell 12%.
- Consolidated gross margin fell four percentage points, reflecting higher royalties, product mix and the absence of a $1.0 million HCV milestone payment received in 2012.
- Sales and marketing expense increased to $46.5 million, including $18.8 million for In-Home HIV advertising and promotion, versus $9.9 million in 2012. Research and development expense declined to $10.9 million from $12.4 million.
- The company continued to report annual net losses and had an accumulated deficit of $173.7 million at year-end.
Outlook, commentary, risks and unusual items
- No formal revenue or earnings guidance is provided in the supplied filing text. Management expected 2014 sales and marketing expense to decline from 2013 levels, OSUR R&D and general and administrative expenses to increase, and DNAG operating expenses to increase across categories.
- The company changed In-Home HIV revenue recognition in December 2013 after concluding it could estimate product returns. The change resulted in a $2.5 million net favorable revenue adjustment in 2013, including recognition of previously deferred shipments; the year-end sales-return and allowance reserve was $279,000.
- The Roche assay collaboration ended in November 2013. Roche paid $8.3 million, recorded as a reduction of operating expense; it may pay up to a further $5.5 million depending on when transitional assay supply ends. OraSure entered a replacement assay development and supply agreement with Thermo Fisher, with initial NIDA-5 sales expected in the second half of 2014.
- In December 2013, DNAG received an FDA warning letter concerning design and development documentation and finished-product acceptance testing, including the regulatory status of the ORAcollect OC-100 device. That device represented less than 0.5% of consolidated revenue in 2013. DNAG had responded and was working with the FDA; the company expected no near-term material financial impact.
- Key risks include regulatory approval and compliance, competition and pricing, adoption of newer products, reliance on government funding and distributors, and sole-source or third-party supply dependencies. The company also cited economic and foreign-exchange exposure. It reported no off-balance-sheet arrangements.
- Other disclosed matters include an employment-related claim against DNAG seeking more than C$500,000, which the company considered without merit, and $9.8 million of contractual obligations at year-end. Management and KPMG reported effective internal control over financial reporting; KPMG issued an unqualified opinion on the financial statements.
Important facts for investors to verify
- How much of 2013 revenue growth and operating-loss improvement is sustainable after excluding the $2.5 million revenue adjustment and $8.3 million Roche settlement.
- Retail sell-through, returns, and future revenue-recognition estimates for the OraQuick In-Home HIV test, along with whether promotional spending can fall without weakening sales.
- Progress resolving the DNAG FDA warning letter and the regulatory status of ORAcollect OC-100.
- Timing, costs, regulatory clearances and commercial launch prospects for Thermo Fisher’s replacement oral-fluid drug assays.
- Whether OraQuick HCV adoption and DNAG growth offset continued pressure in professional HIV, substance-abuse testing, cryosurgery and insurance risk assessment.
- Cash-flow quality, including the Roche settlement and working-capital movements, and whether the stated cash runway remains adequate as planned spending and capital needs evolve.